# India Influenza Diagnostics Market

> India Influenza Diagnostics Market Size, Growth Research Report By Type (PCR Tests, Antigen Tests, Serology Tests, Viral Culture, Rapid Diagnostic Tests), By Product (Reagents, Kits, Instruments, Consumables), By End-user (Hospitals, Clinics, Laboratories, Home Care), and By Technique (Molecular Diagnostics, Immunodiagnostics, Cell Culture) - Competitor Industry Analysis and Trends Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.37%
- **2024:** $ 370.56 Million
- **2025:** $ 401.58 Million
- **2035:** $ 897.44 Million
- **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Thermo Fisher Scientific (US), BD (US), Siemens Healthineers (DE), Cepheid (US), Hologic (US), BioMérieux (FR), Quidel Corporation (US)

**Report ID:** MRFR/MED/55106-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-influenza-diagnostics-market-56872

---

## Market Summary

## **India Influenza Diagnostics Market Overview**

As per MRFR analysis, the India Influenza Diagnostics Market Size was estimated at 428.75 (USD Million) in 2023.The India Influenza Diagnostics Market is expected to grow from 550(USD Million) in 2024 to 1,050 (USD Million) by 2035. The India Influenza Diagnostics Market CAGR (growth rate) is expected to be around 6.055% during the forecast period (2025 - 2035).

### **Key India Influenza Diagnostics Market Trends Highlighted**

The market for influenza diagnostics in India is expanding significantly due to a number of important factors. The need for effective diagnostic techniques has increased as a result of growing knowledge of influenza and its effects. Rapid and precise diagnostic techniques are crucial in healthcare due to the persistent risk of seasonal influenza outbreaks.

Additionally, the Indian government funds programs that enhance public health infrastructure, which facilitates the use of cutting-edge diagnostic tools and enhances illness management in general. The market's opportunities are growing, especially in rural areas with limited access to medical services.

In underserved areas, the availability of reasonably priced diagnostic kits customized to local requirements might improve testing capacity. Furthermore, the expansion of telemedicine in India has created opportunities for remote consultation and diagnostics, offering an opportunity for creative diagnostic solutions that support patient care and rapid results.

Recent developments in technology that improve speed and accuracy have led to a shift in the use of molecular diagnostics in India. Rapid antigen test demand has also increased, especially during the flu season, indicating that healthcare professionals prefer point-of-care testing.

Additionally, it is anticipated that greater public-private sector partnerships would encourage the study and creation of novel diagnostic techniques.

The government's objectives to enhance disease surveillance and fortify the healthcare system are in line with this cooperative endeavor. All things considered, the state of the Indian influenza diagnostics market today points to a bright future driven by advancements in technology and a dedication to public health.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **India Influenza Diagnostics Market Drivers**

### **Increasing Prevalence of Influenza Cases in India**

The rising incidence of influenza in India is a significant driver for the India Influenza Diagnostics Market. According to the National Institute of Virology in Pune, there has been a noticeable uptick in flu cases, with seasonal outbreaks affecting 15 to 20% of the population annually during peak seasons.

This increase leads to higher demand for accurate and rapid diagnostic tests. As a result, healthcare facilities are increasingly investing in advanced diagnostic tools to efficiently manage influenza outbreaks.

For instance, organizations like the Indian Council of Medical Research are actively involved in monitoring and managing influenza trends, contributing to an enhanced focus on diagnostic capabilities within the healthcare sector.

### **Government Initiatives for Disease Prevention**

The Government of India has been proactive in implementing policies aimed at controlling infectious diseases, including influenza. Initiatives such as the National Viral Hepatitis Control Program and the National Health Mission focus on improving disease surveillance and diagnostics.

The Ministry of Health and Family Welfare has allocated significant resources for enhancing laboratory capabilities throughout the country.

Reports indicate that during the fiscal year 2021-2022, the government increased its health expenditure by approximately 23% to facilitate better healthcare infrastructure. Such initiatives provide a robust framework that fosters growth within the India Influenza Diagnostics Market.

### **Growth in Healthcare Infrastructure**

India's healthcare infrastructure has been expanding at a rapid pace, leading to enhanced diagnostic capabilities for influenza and other diseases. Recent government data indicates that the public and private hospital capacity has increased by over 30% since 2015, which includes strengthening laboratory services crucial for influenza diagnostics.

Institutions like the All India Institute of Medical Sciences are setting benchmarks in diagnostic innovation, spurring competition and development within the sector. The growing availability of sophisticated diagnostic tools, combined with a focus on improved patient care, further enhances the growth of the India Influenza Diagnostics Market.

## **India Influenza Diagnostics Market Segment Insights**

### **Influenza Diagnostics Market Type Insights**

The India Influenza Diagnostics Market segmentation based on Type reveals significant insights into the diverse methodologies employed for detecting influenza viruses, reflecting an evolving landscape shaped by technological advancements and increasing public health needs.

PCR Tests have emerged as a crucial testing method due to their high sensitivity and specificity, catering well to the rapid identification of influenza strains. This accuracy is particularly important in India, where it facilitates timely treatment and management of outbreaks, contributing to national healthcare programs aimed at reducing influenza-related morbidity and mortality.

Antigen Tests play a valuable role in rapid diagnostics, primarily because of their quick turnaround time, which is essential in areas with limited resources or during peak influenza seasons. They support public health initiatives by enabling prompt decisions regarding treatment and infection control measures, which are critical in densely populated regions.

Serology Tests furnish additional information on the immune response to influenza, granting healthcare providers insight into past infections and potential herd immunity within communities. This is especially pertinent for formulating vaccination strategies, which are a priority in India's public health agenda.

Viral Culture remains a cornerstone in understanding influenza epidemiology, allowing for the isolation and characterization of viruses. Despite being a more time-consuming process, it offers invaluable data for monitoring viral evolution and helps inform vaccine formulation, thus supporting India's robust public health response framework.

Rapid Diagnostic Tests are gaining traction as they can deliver results within hours, enhancing patient management in resource-limited settings. These tests are significant for early detection during flu season when rapid response is essential.

The growing recognition of influenza's impact on public health in India, combined with rising healthcare accessibility, is driving an uptick in the adoption of these various diagnostic types.

As the country continues to enhance its healthcare infrastructure, the segmentation of the India Influenza Diagnostics Market reflects not only the increasing demand for effective and timely influenza detection but also the opportunities present in each testing methodology to address the challenges posed by seasonal flu outbreaks.

This multi-faceted approach underlines the importance of each diagnostic type in bolstering India's capabilities in influenza surveillance and response, ultimately leading to better health outcomes for the population.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Influenza Diagnostics Market Product Insights**

The India Influenza Diagnostics Market encompasses several product categories including Reagents, Kits, Instruments, and Consumables, which collectively play a critical role in disease detection and management. Reagents are essential for accurate test results, driving demand among laboratories striving for quality diagnostics.

Influenza Kits cater to a wide range of testing needs, allowing for efficiency and rapid response during flu seasons, thereby enhancing healthcare delivery in the region. Instruments used for diagnostics have witnessed advancements, improving the speed and accuracy of results, which is vital for timely patient care in a crowded healthcare landscape.

Consumables, being regularly used supplies, ensure operational continuity, further supporting healthcare facilities across India.

This segmentation showcases the growing importance of specialized products in the ongoing battle against influenza, underlining the market's response to challenges posed by seasonal outbreaks and the need for reliable diagnostic solutions. With healthcare infrastructure evolving, these segments reflect innovation trends, indicating opportunities for growth in the Indian market.

### **Influenza Diagnostics Market****End-use****r Insights**

The End-user segment of the India Influenza Diagnostics Market plays a crucial role in shaping the overall landscape of influenza diagnostics, with hospitals, clinics, laboratories, and home care settings representing the primary avenues for testing and diagnosis.

Hospitals are pivotal due to their comprehensive resources and capabilities, significantly contributing to the evolution of diagnostic practices.

Clinics are important as they offer quick access to testing, enhancing early detection and treatment, especially in bustling urban areas. Laboratories are essential for refining diagnostic accuracy and developing newer testing methodologies, fostering innovations in diagnostics.

Meanwhile, home care has gained prominence, driven by the growing preference for at-home medical services and the emphasis on patient comfort and convenience, especially in rural and semi-urban regions of India. Current trends indicate an increased demand for rapid testing kits and point-of-care diagnostics, largely propelled by the rising awareness and proactive healthcare measures among the populace.

The increasing prevalence of influenza, combined with acute healthcare needs, presents significant opportunities across these segments, as they adapt to technology-driven solutions and the broader shift toward patient-centric care.

The collective performance of these End-users substantially impacts the India Influenza Diagnostics Market growth, aligning with ongoing efforts to bolster public health initiatives and enhance disease management strategies.

### **Influenza Diagnostics Market Technique Insights**

The India Influenza Diagnostics Market, specifically focusing on the Technique segment, is witnessing notable developments, aligning with the nation's increasing healthcare needs. Key techniques employed in this market include Molecular Diagnostics, Immunodiagnostics, and Cell Culture, each playing a significant role in the timely detection of influenza virus strains.

Molecular Diagnostics dominates the landscape due to its high sensitivity and specificity, providing rapid test results that are crucial for effective disease management. Immunodiagnostics also holds substantial importance, leveraging antibody detection to enhance the accuracy of diagnosis.

Cell Culture techniques, while traditionally used, are essential for research purposes and understanding viral behavior. The overall growth of the India Influenza Diagnostics Market is driven by factors such as rising influenza incidents, increasing awareness regarding infectious diseases, and advancements in diagnostic technologies.

Moreover, government initiatives in improving healthcare infrastructure and promoting novel diagnostic methods further bolster market potential. The collective insights from the Technique segment highlight its critical influence on the ongoing improvement in influenza diagnostics, ultimately aiming for better health outcomes across the region.

## **India Influenza Diagnostics Market Key Players and Competitive Insights**

The India Influenza Diagnostics Market has been increasingly gaining traction owing to the rising prevalence of influenza and its associated health complications. The competitive landscape of this market is characterized by various players working on innovative solutions to aid in faster diagnosis and better management of influenza infections.

Companies are investing in research and development to improve diagnostic accuracy, reduce turnaround times, and enhance patient outcomes. The collaboration between healthcare providers and technology-driven diagnostic companies is fostering a rapidly advancing environment that aims to meet the growing demand for reliable and efficient influenza diagnostic tools.

With the emphasis on personalized medicine and targeted therapies, the market is expected to see continued advancements and a shift towards integrated diagnostic solutions.

Sasken Technologies has carved a niche in the India Influenza Diagnostics Market by leveraging its technological expertise and innovation-driven approach. The company is known for providing substantial value through advanced software solutions that enhance the diagnostic processes.

With a strong focus on research and development, Sasken Technologies is well-positioned to address the complexities of influenza diagnostics by offering customized solutions that streamline workflows for healthcare facilities.

Their existing infrastructure and deep domain knowledge provide them with a competitive edge, allowing for the quick adaptation of emerging diagnostic technologies. This strong market presence and commitment to ongoing innovation enable Sasken Technologies to play a significant role in transforming the landscape of influenza diagnostics in India.

Hindustan Antibiotics stands out in the India Influenza Diagnostics Market for its dedication to developing pharmaceutical products that cater to public health needs. The company's product portfolio includes medicines and diagnostic kits essential for managing influenza and associated conditions.

Hindustan Antibiotics has established a solid market presence through its extensive distribution network in India, which allows it to effectively reach healthcare providers and medical institutions. The company's strengths lie in its long-standing reputation for quality and reliability in pharmaceuticals, along with its robust manufacturing capabilities.

Recent efforts in mergers and acquisitions have further strengthened its market position, allowing for enhanced resources and collaborative initiatives aimed at improving influenza diagnostic solutions within the Indian healthcare landscape. By focusing on both production and innovation, Hindustan Antibiotics continues to contribute significantly to the diagnostic needs in the fight against influenza.

### **Key Companies in the India Influenza Diagnostics Market Include**

- Sasken Technologies
- Hindustan Antibiotics
- Mylab Discovery Solutions
- Meril Life Sciences
- bioMérieux
- Zydus Cadila
- Thermo Fisher Scientific
- BD
- Abbott
- Roche
- AIIMS Bhopal
- Transasia BioMedicals
- Siemens Healthineers
- Agappe Diagnostics

## **India Influenza Diagnostics****Market****Developments**

Recent developments in the India Influenza Diagnostics Market have shown significant advancements and growing demand following increased awareness of respiratory diseases. Companies like Mylab Discovery Solutions and Meridian Life Sciences are innovating diagnostic kits that offer rapid results, aligning with government initiatives to improve healthcare infrastructure.

In August 2023, Zydus Cadila announced the launch of its advanced rapid influenza diagnostic test, aiming to enhance early detection and treatment responses within hospitals in India. Meanwhile, Hindustan Antibiotics is also expanding its product line to include novel diagnostics for flu detection, signifying broader collaboration within the sector.

Merger and acquisition activities have been minimal, with no significant transactions reported for the selected companies specifically within the influenza diagnostics segment. However, the overall market valuation for major players, including Thermo Fisher Scientific and Roche, has reportedly grown in 2023, indicating a positive feedback loop enhancing investment and development opportunities.

Additionally, AIIMS Bhopal is engaged in collaborative research aimed at improving influenza diagnostics capabilities, reflecting India's commitment to strengthening its healthcare workforce and technological readiness in response to high disease prevalence rates in the region.

## **India Influenza Diagnostics Market Segmentation Insights**

### **Influenza Diagnostics Market Type****Outlook**

- PCR Tests
- Antigen Tests
- Serology Tests
- Viral Culture
- Rapid Diagnostic Tests

### **Influenza Diagnostics Market Product****Outlook**

- Reagents
- Kits
- Instruments
- Consumables

### **Influenza Diagnostics Market****End-use****r****Outlook**

- Hospitals
- Clinics
- Laboratories
- Home Care

### **Influenza Diagnostics Market Technique****Outlook**

- Molecular Diagnostics
- Immunodiagnostics
- Cell Culture

## Market Drivers

### Rising Healthcare Expenditure

Rising healthcare expenditure in India is another key driver for the influenza diagnostics market. As the country experiences economic growth, there is a corresponding increase in healthcare spending by both the government and private sectors. This trend is reflected in the allocation of funds for healthcare infrastructure, including diagnostic facilities. According to recent reports, healthcare expenditure in India is projected to reach approximately 3.5% of GDP by 2025. This increase is likely to enhance the accessibility and affordability of diagnostic services, thereby stimulating demand for influenza diagnostics. As healthcare systems evolve, the market is expected to benefit from improved diagnostic capabilities and expanded service offerings.

### Government Funding and Support

Government funding and support for healthcare initiatives play a crucial role in the growth of the influenza diagnostics market. The Indian government has been actively promoting public health programs aimed at improving disease surveillance and response capabilities. For instance, the National Health Mission allocates substantial resources for the development and distribution of diagnostic tools. This financial backing not only enhances the availability of influenza diagnostics but also encourages research and development in this field. As a result, the market is likely to witness an influx of innovative diagnostic solutions, further propelling its expansion in the coming years.

### Rising Incidence of Influenza Cases

The increasing incidence of influenza cases in India is a primary driver for the influenza diagnostics market. Seasonal outbreaks and sporadic epidemics contribute to a heightened demand for accurate and timely diagnostic solutions. According to the Ministry of Health and Family Welfare, influenza cases have shown a notable rise, with estimates suggesting that around 10-15% of the population may be affected during peak seasons. This surge necessitates the availability of effective diagnostic tools to facilitate early detection and treatment, thereby driving growth in the influenza diagnostics market. Healthcare providers are increasingly investing in advanced diagnostic technologies to meet this demand, indicating a robust market potential.

### Increased Focus on Preventive Healthcare

The growing focus on preventive healthcare is a significant driver for the influenza diagnostics market in India. With rising awareness about the importance of early detection and prevention of infectious diseases, individuals are increasingly seeking diagnostic services. Public health campaigns and educational initiatives have contributed to a shift in consumer behavior, leading to higher demand for influenza testing. This trend is likely to continue, as more people recognize the value of proactive health management. Consequently, healthcare providers are expanding their diagnostic offerings, which is expected to positively impact the influenza diagnostics market in the near future.

### Technological Innovations in Diagnostic Tools

Technological innovations in diagnostic tools are significantly influencing the influenza diagnostics market. The introduction of rapid diagnostic tests, molecular assays, and point-of-care testing devices has transformed the landscape of influenza detection. These advancements enable healthcare professionals to obtain results within a short timeframe, which is critical for effective patient management. The market is projected to grow at a CAGR of approximately 8-10% from 2025 to 2035, driven by the increasing adoption of these technologies. As healthcare facilities in India strive to enhance their diagnostic capabilities, the demand for innovative solutions is expected to rise, thereby fostering market growth.

## Future Outlook

The [Influenza Diagnostics Market](https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142) in India is projected to grow at 8.37% CAGR from 2025 to 2035, driven by technological advancements, increased healthcare spending, and rising awareness.

**New opportunities:**

- Development of rapid point-of-care testing kits for remote areas.
- Investment in AI-driven diagnostic platforms for enhanced accuracy.
- Expansion of telehealth services integrating influenza diagnostics.

By 2035, the market is expected to achieve substantial growth, reflecting advancements and increased demand.

## Segment Insights

### By Type: PCR Tests (Largest) vs. Rapid Diagnostic Tests (Fastest-Growing)

In the India influenza diagnostics market, PCR Tests hold the largest share, showcasing their dominance in the detection of influenza due to their high sensitivity and specificity. Antigen Tests and Serology Tests follow, while Rapid Diagnostic Tests are becoming increasingly significant, appealing to the need for quick results in clinical settings.

The growth trend for these segments is influenced by several factors, including the rising incidence of influenza outbreaks and increased awareness about early diagnosis. Rapid Diagnostic Tests, in particular, are experiencing the fastest growth owing to their convenience and ability to provide results in less than an hour, aligning with the demands of healthcare facilities for immediate decision-making capabilities.

PCR Tests (Dominant) vs. Rapid Diagnostic Tests (Emerging)

PCR Tests are the cornerstone of influenza diagnostics, being favored for their accuracy and reliability. They are essential in clinical settings, allowing for precise identification of virus strains, which is crucial for effective treatment and vaccination strategies. The tests require skilled personnel and significant laboratory infrastructure, thus portraying their established presence in the market. Conversely, Rapid Diagnostic Tests are emerging as a preferred alternative, particularly in resource-limited settings. Their ability to deliver quick results makes them invaluable during peak influenza seasons, catering to urgent patient needs and enhancing diagnostic accessibility in rural and semi-urban areas. This dynamic signals a shift in the diagnostic landscape, where speed is becoming increasingly important.

### By Product: Kits (Largest) vs. Reagents (Fastest-Growing)

In the India influenza diagnostics market, the product segment is primarily driven by the demand for kits, which currently holds the largest market share. These kits are favored for their convenience and accuracy, making them essential tools in both clinical and at-home settings. On the other hand, reagents are gaining traction, becoming increasingly popular due to advancements in diagnostic technologies, which are enhancing their effectiveness and usability, thereby contributing to their growing market presence.

The growth trends within this segment are influenced by various factors, including rising health awareness, increased government initiatives surrounding influenza diagnostics, and technological improvements that are boosting the performance of these products. The growing emphasis on rapid testing methods is particularly benefiting kits, while the evolving formulations of reagents are making them more versatile and efficient for laboratory use, thus fueling their growth in the market.

Kits (Dominant) vs. Reagents (Emerging)

Kits have established themselves as the dominant product category in the India influenza diagnostics market due to their ease of use and comprehensive testing capabilities. This category encompasses a wide range of products, including rapid tests and PCR kits, which provide reliable results with minimal turnaround time. On the other hand, reagents, although currently categorized as emerging, are witnessing significant growth due to innovative developments that enhance their accuracy and effectiveness. This segment is seeing increased investment in research and development, leading to improved formulations that maximize their diagnostic potential. As healthcare providers seek more efficient tools for influenza detection, the relevance of these reagents is expected to rise, complementing the established demand for kits.

### By End User: Hospitals (Largest) vs. Laboratories (Fastest-Growing)

The India influenza diagnostics market is characterized by a diverse range of end users, among which hospitals represent the largest segment. Hospitals dominate the market owing to their established infrastructure and the high demand for diagnostics in clinical settings. Following hospitals, clinics and laboratories also play significant roles, with laboratories witnessing substantial growth due to increased testing awareness and advancements in technology. Home care services are gradually emerging as more patients prefer self-testing options, adding to the competitive nature of the market.

Growth trends in the India influenza diagnostics market are driven by several factors, including the rising incidence of influenza outbreaks and a heightened focus on early and accurate diagnosis. Laboratories are experiencing the fastest growth, fueled by technological innovations and a shift towards rapid testing methods. Additionally, the increasing awareness of influenza prevention and control in home care settings is propelling the demand for diagnostic solutions, with healthcare systems adapting to meet these evolving needs.

Hospitals (Dominant) vs. Laboratories (Emerging)

Hospitals continue to dominate the end-user segment of the influenza diagnostics market, showcasing their critical role in managing public health challenges, especially during influenza seasons. With ample resources and specialized personnel, they offer comprehensive diagnostic services that are essential for timely patient care. Conversely, laboratories are emerging as a vital segment due to their ability to implement cutting-edge diagnostic techniques and streamline testing processes. The rise of digital health solutions has further enhanced their capabilities, making them instrumental in facilitating faster and more accurate influenza diagnostics. As healthcare systems evolve, both hospitals and laboratories will play pivotal roles in ensuring effective influenza management.

### By Technique: Molecular Diagnostics (Largest) vs. Immunodiagnostics (Fastest-Growing)

In the India influenza diagnostics market, molecular diagnostics has emerged as the largest segment, capturing a significant share due to its high accuracy and rapid results. Immunodiagnostics, while smaller in current market share, is quickly expanding as healthcare providers increasingly adopt these solutions for their enhanced efficiency.

The growth trends in this segment are driven by rising awareness about influenza prevention and accurate diagnosis. The demand for faster and more reliable diagnostic tools is pushing technological advancements, particularly in molecular diagnostics. Additionally, the healthcare infrastructure's expansion and increasing government initiatives to promote influenza vaccination and diagnostics are set to further fuel the segment's growth.

Molecular Diagnostics (Dominant) vs. Immunodiagnostics (Emerging)

Molecular diagnostics stands out as the dominant technique in the India influenza diagnostics market, renowned for its capability to detect viral RNA and DNA with high sensitivity and specificity. This technique employs advanced technologies such as PCR, which enables rapid diagnosis and minimizes the risk of false negatives. In contrast, immunodiagnostics represents an emerging segment characterized by its easy-to-use tests, which typically provide qualitative results for influenza detection. Although this segment is growing rapidly, it faces competition from the highly accurate molecular methods. Both segments play crucial roles in enhancing patient care, with molecular diagnostics leading in terms of reliability.

## Competitive Benchmarking

The influenza diagnostics market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Roche Diagnostics (CH), Abbott Laboratories (US), and Thermo Fisher Scientific (US) are at the forefront, leveraging their technological expertise to enhance diagnostic accuracy and speed. Roche Diagnostics (CH) focuses on integrating advanced molecular techniques into their product offerings, which positions them favorably in a market that demands rapid and reliable results. Meanwhile, Abbott Laboratories (US) emphasizes a strategy of local manufacturing and distribution, which not only reduces costs but also enhances supply chain efficiency, thereby improving their market responsiveness. Thermo Fisher Scientific (US) appears to be concentrating on digital transformation initiatives, aiming to streamline operations and improve customer engagement through innovative digital platforms.The business tactics employed by these companies reflect a moderately fragmented market structure, where localized manufacturing and supply chain optimization are pivotal. The collective influence of these key players fosters a competitive environment that encourages continuous improvement and innovation. As companies strive to differentiate themselves, the focus on localized production and efficient logistics becomes increasingly critical, allowing them to respond swiftly to market demands and regulatory changes.

In August  Roche Diagnostics (CH) announced the launch of a new rapid influenza diagnostic test that utilizes advanced molecular technology, significantly reducing the time required for results. This strategic move not only enhances their product portfolio but also reinforces their commitment to providing timely diagnostics, which is essential in managing influenza outbreaks. This introduction of the test is likely to strengthen Roche's market position by addressing the growing demand for rapid testing solutions.

In September  Abbott Laboratories (US) expanded its manufacturing capabilities in India, aiming to increase the production of its influenza diagnostic kits. This expansion is strategically important as it allows Abbott to meet the rising domestic demand while also positioning itself as a key player in the regional market. By enhancing local production, Abbott can ensure a more reliable supply chain and potentially lower costs, which could translate into competitive pricing strategies.

In October  Thermo Fisher Scientific (US) entered into a partnership with a leading Indian healthcare provider to develop a comprehensive influenza surveillance program. This collaboration is indicative of a broader trend towards strategic alliances that enhance data sharing and improve public health responses. By leveraging local expertise and resources, Thermo Fisher aims to bolster its presence in the Indian market while contributing to the overall improvement of influenza diagnostics and management.

As of November  the competitive trends in the influenza diagnostics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are becoming more prevalent, facilitating knowledge exchange and resource sharing among key players. Looking ahead, the competitive differentiation in this market is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and the reliability of supply chains. Companies that can effectively harness these trends will likely secure a more robust market position in the future.

## Recent News & Developments

Recent developments in the India Influenza Diagnostics Market have shown significant advancements and growing demand following increased awareness of respiratory diseases. Companies like Mylab Discovery Solutions and Meridian Life Sciences are innovating diagnostic kits that offer rapid results, aligning with government initiatives to improve healthcare infrastructure.

In August 2023, Zydus Cadila announced the launch of its advanced rapid influenza diagnostic test, aiming to enhance early detection and treatment responses within hospitals in India. Meanwhile, Hindustan Antibiotics is also expanding its product line to include novel diagnostics for flu detection, signifying broader collaboration within the sector.

Merger and acquisition activities have been minimal, with no significant transactions reported for the selected companies specifically within the influenza diagnostics segment. However, the overall market valuation for major players, including Thermo Fisher Scientific and Roche, has reportedly grown in 2023, indicating a positive feedback loop enhancing investment and development opportunities.

Additionally, AIIMS Bhopal is engaged in collaborative research aimed at improving influenza diagnostics capabilities, reflecting India's commitment to strengthening its healthcare workforce and technological readiness in response to high disease prevalence rates in the region.

## Report Scope

| MARKET SIZE 2024 | 370.56(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 401.58(USD Million) |
| MARKET SIZE 2035 | 897.44(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.37% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Thermo Fisher Scientific (US), BD (US), Siemens Healthineers (DE), Cepheid (US), Hologic (US), BioMérieux (FR), Quidel Corporation (US) |
| Segments Covered | Type, Product, End User, Technique |
| Key Market Opportunities | Integration of rapid testing technologies enhances efficiency in the influenza diagnostics market. |
| Key Market Dynamics | Rising demand for rapid influenza diagnostics drives innovation and competition among local and global manufacturers. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the market valuation of the India influenza diagnostics market in 2024?**
A: The market valuation was $370.56 Million in 2024.

**Q: What is the projected market valuation for the India influenza diagnostics market by 2035?**
A: The projected valuation for 2035 is $897.44 Million.

**Q: What is the expected CAGR for the India influenza diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 8.37% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the India influenza diagnostics market?**
A: Key players include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, BD, Siemens Healthineers, Cepheid, Hologic, BioMérieux, and Quidel Corporation.

**Q: What were the valuations for PCR tests in the India influenza diagnostics market in 2024?**
A: The valuation for PCR tests was $100.0 Million in 2024, projected to reach $240.0 Million by 2035.

**Q: How did the antigen tests segment perform in 2024?**
A: The antigen tests segment had a valuation of $80.0 Million in 2024, with a projection of $180.0 Million by 2035.

**Q: What is the market size for rapid diagnostic tests in the India influenza diagnostics market?**
A: The rapid diagnostic tests segment was valued at $110.56 Million in 2024, expected to grow to $287.44 Million by 2035.

**Q: What were the valuations for kits in the product segment of the market in 2024?**
A: The kits segment had a valuation of $111.84 Million in 2024, projected to increase to $264.44 Million by 2035.

**Q: Which end user segment had the highest valuation in 2024?**
A: The hospitals segment had the highest valuation at $111.22 Million in 2024, expected to reach $263.12 Million by 2035.

**Q: What is the projected growth for molecular diagnostics in the India influenza diagnostics market?**
A: Molecular diagnostics was valued at $148.56 Million in 2024, with projections indicating growth to $352.44 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-influenza-diagnostics-market-56872*